Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC). This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results